SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing aggressive momentum driven by growing institutional conviction that CPU demand is a critical, under-modeled component of the broader AI infrastructure buildout. The community is actively debating the stock's elevated valuation against its structural role in mobile-to-AI architecture, with traders focused on positioning around potential earnings catalysts and managing volatility in this high-beta semiconductor play.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is experiencing intense volatility and speculative fervor as investors position themselves ahead of the upcoming earnings report, with the community sharply divided between those betting on a major short squeeze and others bracing for a post-earnings sell-off. Sentiment is fueled by debate over the company's valuation versus its long-term potential in quantum computing, while technical traders closely monitor institutional volume and significant short interest as key drivers for near-term price swings.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc is generating significant community interest ahead of its upcoming earnings call, with investors closely watching for a potential turnaround driven by improved cost discipline, subscription growth, and advancements in AR and AI integration. The stock is experiencing high volatility as participants weigh these long-term catalysts against ongoing concerns regarding user growth and intense competition in the social media space.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corporation is experiencing intense volatility driven by significant institutional selling of a major shareholder's stake, though community members are debating whether this marks a final clearance of supply or a signal of deeper structural concerns. While some investors view the current price action as a tactical accumulation opportunity ahead of upcoming earnings and potential sector-wide interest, others remain skeptical about management's ability to drive sustained profitability.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as investors react to a powerful earnings beat characterized by massive year-over-year growth and exceptional profit margins driven by its AI-powered AXON engine. While the stock faces volatility and community debate over its software sector classification, bullish sentiment remains centered on its aggressive e-commerce expansion and strong cash flow generation.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is gaining significant momentum following NOAA's official ruling that its deep-seabed mining application is fully compliant, a key regulatory milestone that clears a path toward potential commercial operations by 2027. Community members are actively debating the stock's long-term potential as a critical player in U.S. mineral sovereignty and are closely watching for follow-up news regarding commercial agreements and federal permitting timelines.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility and heavy short-interest pressure as investors weigh recent clinical data updates for its siRNA pipeline against ongoing regulatory uncertainties surrounding its core gene therapy franchise. While the community remains sharply divided, active discussions center on the company's attractive valuation relative to its revenue base and the potential for a short squeeze if upcoming earnings and regulatory filings provide the necessary momentum.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV investors are locked in a heated debate ahead of earnings, with bulls pointing to the Disney partnership and potential for a short squeeze, while bears argue that persistent subscriber losses and poor management justify the stock's significant decline. The community remains deeply divided, focusing heavily on whether the company can finally hit profitability or if it will continue its long-term downward trend.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is experiencing extreme volatility as investors weigh strong operational fundamentalsincluding a 200M share buyback and margin expansionagainst a controversial short report that the company has formally refuted. The community is actively debating the credibility of these allegations, with many viewing the sharp sell-off as a significant buying opportunity while others express frustration over the sustained pressure on the stock price.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Semiconductor bears are facing intense pressure as the sector continues a relentless, momentum-driven melt-up that ignores valuation concerns and persistent market-wide euphoria. Investors are actively debating the sustainability of this rally, with many expressing deep frustration over after-hours price spikes and a growing disconnect between sector valuations and traditional financial fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Grace was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage.</li><li>However, the FDA issued a letter to it on Thursday, citing issues in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of its application.</li><li>Analysts from Craig-Hallum and TD Cowen slashed price targets on the stock on Friday following the FDA decision.</li></ul>Shares of Grace Therapeutics (GRCE) are on track for their worst week since Sept. 2020, after the U.S. Food and Drug Administration refused to approve its experimental drug for the treatment of a severe form of acute brain injury, sparking price target cuts.Shares of the company are down 49% this week, if losses hold.<h2 class="st-heading-2">FDA Rejection</h2>Grace was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH), or bleeding over the surface of the brain in the space between the brain and the skull as a result of a ruptured brain aneurysm.However, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/grce-stock-plunges-after-fda-rejects-brain-injury-drug-company-says-concerns-are-fixable/cZBQevVReTT">issued </a>a letter to it on Thursday, citing issues in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of its application. The agency highlighted leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at the company’s contract manufacturing organization, it said.<h2 class="st-heading-2">Wall Street Weighs In</h2>Craig-Hallum lowered the firm's price target on Grace Therapeutics to $4 from $11 and kept a ‘Buy’ rating on the shares following the announcement. The firm believes Grace has enough runway to address the deficiencies highlighted by the FDA and an application resubmission, though shares are unlikely to move higher until further visibility is provided, it said.TD Cowen analyst Stacy Ku also lowered the firm's price target on Grace Therapeutics to $8 from $12 and kept a ‘Buy’ rating on the shares. The firm noted that GTx-104's rejection is related to CMC, with no requests for additional clinical data. Management will seek a meeting with the FDA, which should clarify resubmission timelines, the analyst said. The firm assumes a roughly 12-month delay, with potential for faster resolution.<h2 class="st-heading-2">Grace Chimes In</h2>“We are confident in the robust data package supporting our NDA (application) submission, and that the CMC issues identified by the FDA can be successfully addressed in our resubmission,” CEO Prashant Kohli said on Thursday following the receipt of the FDA letter.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around GRCE stock stayed within ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user highlighted that the issues cited by the FDA are fixable and the stock will bounce back up.<stembedurl>https://www.stocktwits.com/h8ster/message/651317731</stembedurl>Another user dismissed the rejection and instead highlighted possible risks of dilution from capital raising initiatives.<stembedurl>https://www.stocktwits.com/Stockseeking/message/651266436</stembedurl><a href="https://stocktwits.com/symbol/GRCE">GRCE stock</a> is down 8% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cmps-on-track-for-best-week-ever-on-fda-push-for-psychedelics/cZBhaQDReck">CMPS On Track For Best Week Ever On FDA Push For Psychedelics</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

GRCE Stock On Track For Worst Week In 5.5 Years —  What’s Driving The Selloff?

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.

Equity

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.


<ul class="summary-bullets"><li>FDA cited issues in the chemistry, manufacturing, and controls (CMC) and non-clinical sections of the company’s application.</li><li>The agency, however, did not request additional clinical data, the company highlighted.</li><li>The company expects to have a meeting with the FDA to determine the next steps ahead.</li></ul> Shares of Grace Therapeutics Inc. (GRCE) closed 45% lower on Thursday after the U.S. Food and Drug Administration refused to approve its experimental drug for the treatment of a severe form of acute brain injury.Grace was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH), or bleeding over the surface of the brain in the space between the brain and the skull as a result of a ruptured brain aneurysm. aSAH accounts for about 5% of all strokes and affects about 42,500 patients in the U.S., according to Grace. &nbsp;<h2 class="st-heading-2">Why The Rejection?</h2>The company said that the FDA issued it a complete response letter, in which the agency cites issues in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of the application. The agency highlighted leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at the company’s contract manufacturing organization, it said.The agency, however, did not request additional clinical data, the company highlighted. Grace submitted its application with positive results from the Phase 3 STRIVE-ON safety trial, which compared GTx-104, an injectable form of nimodipine, with its oral version. The study met its primary endpoint, showing a 19% reduction in clinically significant hypotension among patients treated with GTx-104.<h2 class="st-heading-2">Executive Optimism</h2>“We are confident in the robust data package supporting our NDA submission, and that the CMC issues identified by the FDA can be successfully addressed in our resubmission,” CEO Prashant Kohli said. The company expects to have a meeting with the FDA to determine the next steps ahead.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around GRCE stock jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels.A Stocktwits user expressed optimism for the company fixing the issues.<stembedurl>https://www.stocktwits.com/Tradebub/message/651205728</stembedurl>Another user expressed optimism for the stock to rally while the company resubmits its application.<stembedurl>https://www.stocktwits.com/46e123/message/651201565</stembedurl><a href="https://stocktwits.com/symbol/GRCE">GRCE stock</a> has added 2% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-spacex-merger-is-coming-biographer-tells-investors-you-are-investing-in-elon-musk/cZBQ47MReTR">Tesla-SpaceX Merger Is Coming: Biographer Tells Investors, ‘You’re Investing In Elon Musk, Not Procter &amp; Gamble’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable

Grace Therapeutics was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage. 

<ul class="summary-bullets"><li>Grace Therapeutics’ NDA for GTx-104 was accepted by FDA last August</li><li>GTx-104 already received Orphan Drug Designation, which could grant seven years of market exclusivity in the U.S. if approved.</li><li>Patients on GTx-104 also recorded fewer ICU readmissions and shorter hospital stays, the company said.</li></ul>Shares of Grace Therapeutics (GRCE) are gaining investor attention ahead of a key decision from the U.S. Food and Drug Administration on its treatment for the highly fatal aneurysmal subarachnoid hemorrhage, with a verdict expected on April 23.<a href="https://stocktwits.com/symbol/INBX">GRCE shares</a> traded 1.7% higher in pre-market trading on Wednesday.<h2 class="st-heading-2">Data Shows Fewer ICU Admissions</h2>Last August, Grace Therapeutics announced that the FDA accepted its New Drug Application (NDA) for GTx-104, a potential treatment for patients with aneurysmal subarachnoid hemorrhage (aSAH), setting a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2026A PDUFA date is the FDA’s target date for making a decision on a drug application, which allows the drug to be marketed in the U.S.The submission was backed by positive results from the Phase 3 STRIVE-ON safety trial, which compared GTx-104, an injectable form of nimodipine, with its oral version. The study met its primary endpoint, showing a 19% reduction in clinically significant hypotension among patients treated with GTx-104.Patients on GTx-104 also recorded fewer ICU readmissions and shorter hospital stays. Safety outcomes were comparable between the two groups, with no new concerns identified.GTx-104 has also received Orphan Drug Designation, which could grant seven years of market exclusivity in the U.S. if approved. The designation could also result in the waiver of FDA application user fees.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘neutral’ from ‘bearish’ a day earlier, amid ‘high’ message volumes.One bullish user highlighted a potential rally given the “super low float.”<stembedurl>https://stocktwits.com/CharlieeMungerTWITS/message/650871175</stembedurl>Another user weighed in on trading in the stock if the approval was granted.<stembedurl>https://stocktwits.com/kintaro712/message/650971705</stembedurl>Year-to-date, the stock has gained around 37%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

GRCE Stock In Spotlight Ahead Of FDA Verdict On Brain Bleed Drug This Week 

The FDA set a Prescription Drug User Fee Act target action date of April 23 to rule on GTx-104, a potential treatment for patients with aneurysmal subarachnoid hemorrhage.

GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears

Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Grows By 300.8%

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling...

Grace Therapeutics (NASDAQ:GRCE) Announces Earnings Results

Grace Therapeutics (NASDAQ:GRCE - Get Free Report) posted its earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus...

Grace Therapeutics (GRCE) Expected to Announce Quarterly Earnings on Thursday

Grace Therapeutics (NASDAQ:GRCE) will be releasing its Q3 2026 earnings before the market opens on Thursday, February 12. (View Earnings Report at...

Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Up 34.6% in January

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE) Sees Significant Increase in Short Interest

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 31,816 shares...

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.23	--	--	N/A
Q3 '25	-$0.28	-$0.14	50.00%	BEAT
Q2 '25	-$0.25	-$0.06	76.11%	BEAT
Q1 '25	-$0.22	-$0.21	4.55%	BEAT
Q4 '24	-$0.28	$0.11	139.64%	BEAT

GRCE
Grace Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest GRCE News

GRCEGrace Therapeutics Inc.